🔗 Share this article

The first new treatments for gonorrhoea in many years are being hailed as a "significant breakthrough" in the fight against superbug strains of the bacteria, according to scientists.

A Worldwide Health Concern

Gonorrhoea infections are escalating around the world, with figures suggesting in excess of 82 million new cases annually. Notably increased rates are reported in the African continent and nations within the WHO's Western Pacific region, which spans from Mongolia and China to New Zealand. In England, cases have reached a all-time high, while infection numbers across Europe in 2023 were significantly elevated compared to figures for 2014.

“The authorization of novel therapies for gonorrhoea is an significant and necessary step in the context of increasing worldwide cases, the spread of superbugs and the extremely scarce therapeutic options at this time.”

Medical experts are deeply concerned about the surge in drug-resistant strains. The World Health Organization has designated it as a "critical concern". Ongoing monitoring showed that resistance to key first-line drugs like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

A Pair of Novel Treatment Options Secure Authorization

Zoliflodacin, alternatively called Nuzolvence, was authorized by the American regulatory agency in December for combating gonorrhoea. This infection can lead to serious health problems, including the inability to conceive. Researchers hope that specific application of this new drug will help slow the spread of drug resistance.

Another new antibiotic, developed by the drugmaker GSK, gained clearance in close succession. This drug, which is additionally indicated for urinary tract infections, was proven in research to be successful in treating superbug versions of the gonorrhoea bacteria.

A Novel Development Model

Zoliflodacin stemmed from a new, not-for-profit approach for medication research. The non-profit organisation GARDP partnered with the pharmaceutical company its industry partner to see it through.

“This approval represents a significant shift in the treatment of multidrug-resistant gonorrhoea, which until now has been evolving faster than our drug pipeline.”

Research Study Results and Worldwide Availability

According to results detailed in a major medical journal, the new drug cured the vast majority of genital gonorrhoea infections. This establishes an equal footing with the existing first-line therapy, which involves an injection and a pill. The trial enrolled nearly 1,000 patients from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its development partnership, GARDP has the authority to make available and distribute the drug in numerous developing nations.

Clinicians directly involved have shared positive views. Having a single-dose, oral treatment such as this is seen as a "critical tool" for gonorrhoea control. This is viewed as vital to reduce the burden of the illness for individuals and to halt the transmission of highly drug-resistant gonorrhoea worldwide.